Health Trials

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

ConditionsNon Hodgkin LymphomaRefractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell LymphomaHigh Grade B-cell LymphomaCentral Nervous System LymphomaPrimary Mediastinal B-cell Lymphoma (PMBCL)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMiltenyi Biomedicine GmbH

About this trial

This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

Eligibility criteria

Qualifiers

Received zamtocabtagene autoleucel in a North American Miltenyi Biomedicine-sponsored clinical study and have not withdrawn consent to be followed or been deemed lost to follow-up.

Provided written informed consent to participate in this study.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Long-term Follow-Up

Treatment groups

150 Participants
are divided into 1 treatment group

Sponsors and collaborators

Miltenyi Biomedicine GmbH

Lead sponsor

Source ClinicalTrials.gov